Stockreport

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported data highlighting the clinical benefits of camonsert [Read more]